Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TAX2 |
| Synonyms | |
| Therapy Description |
TAX2 is a cyclic peptide antagonist of the TSP1/CD47 interaction, which potentially inhibits angiogenesis, induces anti-tumor immune response, and reduces tumor growth (PMID: 26046793, PMID: 34638503). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TAX2 | TAX-2|TAX 2|AP-01 | TAX2 is a cyclic peptide antagonist of the TSP1/CD47 interaction, which potentially inhibits angiogenesis, induces anti-tumor immune response, and reduces tumor growth (PMID: 26046793, PMID: 34638503). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07688148 | Phase Ib/II | TAX2 | A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours (APM-CT001) | Not yet recruiting | FRA | BEL | 0 |